2016 the 5th International (Guangzhou) Forum for Cancer Treatment was convened at Jinan University School of Medicine affiliated Fuda Cancer Hospital on July 2. The forum brought together over 200 experts at home and abroad, over 20 of whom delivered keynote speeches on the application of cryosurgery, IRE treatment, and stem cell in the field of cancer treatment. The forum consisted of the following sections:
Section 1: new thoughts and strategies on cancer treatment
Section 2: cryoablation for cancer
Section 3: Irreversible Electroporation therapy in cancer treatment
Section 4: immunotherapy in cancer treatment
Prof. VAY LIANG W. (BILL) GO, director of UCLA Center for Excellence in Pancreatic Disease, David Geffen School of Medicine at UCLA, editor-in-chief of Pancreas started section 1 with the keynote speech titled Pancreatic Cancer Research: Gaps and Opportunities.
Dr. AKIHIRO SHIMOSAKA, chairperson of Asian Cellular Therapy Organization, Seceretary of International Society for Cellular Therapy Asian Region, delivered a keynoted speech titled Importance of Regulations and Ethics Committee for Cellular Therapy.
Prof. LU YOUYONG, second grade professor of Beijing Cancer Hospital, senior PI of Laboratory of Molecular Oncology, secretary general of the Chinese Cancer Genome Consortium shared with the participating experts the presentation titled Cobining ERBB4 with TP53 and RAS Signaling Predicts Clinical Outcome in Subtypes of Gastric Cancer.
Prof. FRISCA LEE YAN-GO, director of the Center for Sleep, School of Medicine, University of California introduced Sleep Disturbance in Cancer Patients. FRISCA, the wife of VAY LIANG W. (BILL) GO, has her ancestral home in Taishan, Guangdong. She lived in Philippines when she was a child. In 1963, then 24-year-old FRISCA went to America from Philippines by a ship. She worked her way from an intern, a nurse to a medical expert.
Prof. Han Weidong, oncology doctoral tutor, director of Laboratory of Molecular Immunology, Chinese PLA General Hospital, delivered a keynote speech titled Review to Immune Therapy in Oncology.
The development of imaging technology has prompted the rise of interventional oncology, which marks a remarkable advance in cancer treatment. Modern cryoablation which is represented by argon-helium cryosurgery was emerged in the late period of last century. Irreversible Electroporation, came out in recent years, have gained rapid development. Both of the ablation methods have brought hope of life for patients who cannot tolerate surgery or who have unresectable tumors. At the forum, several experts shared their experience in performing cryoablation and IRE.
Prof. NIKOLAI KORPAN, honorary president of International Society of Cryosurgery, President of Austria Society of Cryosurgery, chairman of International Institute for Cryosurgery, delivered a keynoted speech titled A Novel BioCryoImmunological Concept in Science and Medicine: Discovery, Hypothesis & Evolution.
Prof. HARUO ISODA, Brain & Mind Research Center, Nagoya University, Department of Brain & MindScience, Nagoya University Graduate School of Medicine shared with the participating experts Newly Developed Cryosurgical System Using Thermosiphon: A Fundamental Study and An Animal Experiment.
Prof. Xu Kecheng, chief president of Jinan University School of Medicine affiliated Fuda Cancer Hospital delivered a keynote speech titled Survival Analysis of 8000 Cases of Cancer Treated by Percutaneous Cryosurgery, which introduced the efficacy of cryosurgery performed by the hospital. It’s reported that Jinan University School of Medicine affiliated Fuda Cancer Hospital is the first in mainland China to have introduced the cryotherapy technology. As of now, FUDA has performed the most cases of cryosurgery in the world and has accumulated rich experience in treating cancer with cryosurgery.
Prof. Huang Kaiwen, director and chief executive of Minimally In vasive Treatment Center for Cancer, Medical School Affiliated Hospital, Taiwan University, shared with the participating experts US Guided IRE for Cancer Treatment. Prof, Xiao Yueyong from the Radiology Department, General Hospital of Peple’s Liveration Army, shared with the audience Basic Research and Clinical Application of Irreverisible Electroporation Ablation in Cancer Treatment.
During the session of the forum, an IRE operation was also broadcast live. The surgeon was Prof. Niu Lizhi, executive president of Jinan University School of Medicine Affiliated Fuda Cancer Hospital. The patient, a 55-year old Hong Kong SAR resident, had repeated fever since early 2016 and was diagnosed with pancreatic cancer. Moreover, the patient was also found to have right thyroid nodules. On July 2nd, 2016, Prof. Niu Lizhi performed IRE on pancreatic tumor and right thyroid nodules. The procedure went smoothly and intraoperative bleeding was 2ml.
At present, over 6,000 cases of IRE treatments have performed for patients with tumor in parenchymal organs, including pancreas, liver, prostate, etc. It is especially advantageous in treating unresectable liver cancer and pancreatic cancer and tumors that are close to big blood vessels, hepatic hilar region, bile duct, and ureter.